Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dalcinonacog alfa LA by Gyre Therapeutics for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Dalcinonacog alfa LA is under clinical development by Gyre Therapeutics and currently in Phase II for Hemophilia B (Factor IX...